Puretech Health plc (PRTC) Ordinary 1p
3.80p
(3.15%)
- Add to watchlist
- Create an alert
- This stock can be held in a
3.80p
(3.15%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
3.80p
(3.15%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
120.00p
124.40p
160.00p
£300.65 million
120.60p
120.00p
100.40p
7.68
0.40p (0.33%) Previous:
0.40p
248,109
n/a
7,500
Performance
| 1 week 1W | 2.11% | 1 year 1Y | 24.63% |
|---|---|---|---|
| 1 month 1M | 1.15% | 2 years 2Y | 17.85% |
| 3 months 3M | 12.71% | 3 years 3Y | 55.5% |
| 6 months 6M | 8.91% | 5 years 5Y | 66.78% |
Performance figures are based on the previous close price. Past performance is not an indication of future performance.
Fundamental data
| Year ending: | 31/12/2024 | 31/12/2023 |
|---|---|---|
| Revenue ($m) | 4.83 | 3.33 |
| Profit before tax ($m) | 23.77 | (36.10) |
| Adjusted EPS (¢): | 21.00 | (24.00) |
| P/E ratio | 9.60 | n/a |
| PEG | n/a | n/a |
| EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: US dollar
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
There are no documents available for this stock.
-
PureTech appoints Robert Lyne as permanent CEO
18 December 2025 08:43
-
PureTech Health contract revenues surge, cuts costs as portfolio strategy evolves
28 August 2025 07:35
-
PureTech launches respiratory development vehicle Celea Therapeutics
12 August 2025 12:04
-
PureTech Appoints Robert Lyne as CEO
18 December 2025 07:00
-
Results of AGM on June 16, 2025 – Update Statement
10 December 2025 17:41
-
Holding(s) in Company
10 December 2025 17:30
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.